
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Bioimmunotherapy, Sections of Immunobiology and Drug Carriers [A-M. S., A. M. T.] and Immunotherapy [S. E., E. A. G.] and Department of Biostatistics [L. D. B.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030
N-(4-Hydroxyphenyl)retinamide (4-HPR) induces apoptosis in breast cancer cells; however, the molecular basis by which 4-HPR induces apoptosis is not well understood. In breast cancer cells, nitric oxide (NO) is predominantly an apoptotic inducer. Apoptotic agents, such as phorbol ester, tumor necrosis factor-
, and peptide hormones, have been shown to increase NO production in breast cancer cells. Therefore, we hypothesized that the production of NO is vital for 4-HPR to induce apoptosis in breast cancer cells. We found that 4-HPR induced NO production in a dose-dependent manner in all of the breast cancer cell lines tested. The degree of growth inhibition and apoptotic induction by 4-HPR was directly correlated with the amount of NO produced. To prove that NO is essential for 4-HPR to induce apoptosis, breast cancer cells were coincubated with a competitive NO synthase (NOS) inhibitor, NG-monomethyl-L-arginine (L-NMMA), and 4-HPR. L-NMMA prevented 4-HPR from inducing inhibitory effects, indicating that NO is crucial for 4-HPR to induce its apoptotic effects in breast cancer cells. IFNs and tamoxifen (TAM) have been shown to potentiate 4-HPR effects in breast cancer cells. Both IFN-
and TAM enhanced the ability of 4-HPR to induce NO production in breast cancer cells, which was correlated with increased apoptosis. Alone, 4-HPR increased expression of both inducible NOS (NOSII) and endothelial NOS (NOSIII). When combined with 4-HPR, IFN-
and TAM enhanced NOSII expression. Thus, we have identified a novel mechanism by which 4-HPR induces apoptosis in breast cancer cells, i.e., by increasing NOS expression to induce NO production.
This article has been cited by other articles:
![]() |
H. Kadara, E. Tahara, H.-J. Kim, D. Lotan, J. Myers, and R. Lotan Involvement of Rac in Fenretinide-Induced Apoptosis Cancer Res., June 1, 2008; 68(11): 4416 - 4423. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-H. Hung, Y.-S. Lu, Y.-C. Wang, Y.-H. Ma, D.-S. Wang, S. K. Kulp, N. Muthusamy, J. C. Byrd, A.-L. Cheng, and C.-S. Chen FTY720 Induces Apoptosis in Hepatocellular Carcinoma Cells through Activation of Protein Kinase C {delta} Signaling Cancer Res., February 15, 2008; 68(4): 1204 - 1212. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. Simeone, S. Colella, R. Krahe, M. M. Johnson, E. Mora, and A. M. Tari N-(4-Hydroxyphenyl)retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells Carcinogenesis, March 1, 2006; 27(3): 568 - 577. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. Simeone, Y.-J. Li, L. D. Broemeling, M. M. Johnson, M. Tuna, and A. M. Tari Cyclooxygenase-2 Is Essential for HER2/neu to Suppress N- (4-Hydroxyphenyl)retinamide Apoptotic Effects in Breast Cancer Cells Cancer Res., February 15, 2004; 64(4): 1224 - 1228. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Crowell, V. E. Steele, C. C. Sigman, and J. R. Fay Is Inducible Nitric Oxide Synthase a Target for Chemoprevention? Mol. Cancer Ther., August 1, 2003; 2(8): 815 - 823. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |